Investing
Boston Scientific (BSX): Saving Itself Through Auctioning Off Pieces
Published:
Boston Scientific (BSX) did it shareholders a terrible disservice buy buying Guidant in a bidding war with Johnson & Johnson. It now has long-term debt of almost $8.3 billion. Troubles in its stent business have hurt earnings and the company lost money last quarter.
BSX shares which went from $13 five years ago to $44 in mid-2004, are back to $13. And, all of this is because management thought M&A would make the company bigger through cutting costs at an acquired company and relying on "synergy".
Well, it did not work, and now BSX has to auction off pieces of the company to save its skin and cover its debt service.
Boston Scientific has just sold its cardiac surgery and vascular surgery units off to Swedish company Getinge for $750 million in cash. These units went because, according to BSX, they were non-core assets.
When the going gets tough, all assets become "non-core".
Douglas A. McIntyre
Are You Ahead, or Behind on Retirement?
If you’re one of the over 4 Million Americans set to retire this year, you may want to pay attention. Many people have worked their whole lives preparing to retire without ever knowing the answer to the most important question: am I ahead, or behind on my goals?
Don’t make the same mistake. It’s an easy question to answer. A quick conversation with a financial advisor can help you unpack your savings, spending, and goals for your money. With Zoe Financial’s free matching tool, you can connect with trusted financial advisors in minutes.
Why wait? Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.